Literature DB >> 8429821

Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain.

R P Yasuda1, W Ciesla, L R Flores, S J Wall, M Li, S A Satkus, J S Weisstein, B V Spagnola, B B Wolfe.   

Abstract

A portion of the cDNA sequence corresponding to the third intracellular loop of either the m4 or m5 muscarinic cholinergic receptor was ligated into the pRIT23 or pET-3a expression vector, respectively. The expressed fusion proteins were purified and used to develop selective polyclonal antisera to the m4 and m5 muscarinic receptors. These antisera were used in an immunoprecipitation protocol to examine quantitatively the distribution of receptor subtypes in regions of rat brain. The density of m4 receptors in rat brain increased in the caudal to rostral direction. The highest levels of m4 receptors were detected in the striatum (1280 fmol/mg) and olfactory tubercle (750 fmol/mg). Low levels of m5 receptors were detected in several brain regions (< 25 fmol/mg). By combining the previously determined receptor densities for the m1, m2, and m3 receptors and results obtained with the newly developed antisera to m4 and m5 receptors, it was determined that 86-99% of the [3H]quinuclidinyl benzilate binding sites in several brain regions were immunoprecipitated. In addition to measuring receptor densities in rat brain, the immunoprecipitation protocol was used to quantify muscarinic receptor levels in tissues reported to express mRNA encoding the m4 receptor. Thus, although only m4 mRNA has been detected in rabbit lung, NG108-15 cells, and N1E-115 cells, both rabbit lung and NG108-15 cells possess both m2 (rabbit lung, 27%; NG108-15 cells, 31%) and m4 (rabbit lung, 55%; NG108-15, 42%) receptors, whereas N1E-115 cells were found to have both m1 (15%) and m4 (65%) receptors. These antisera will be useful in studies of receptor regulation and in determining alterations in density that may occur after pharmacological or physiological manipulations and in various disease states.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429821

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  54 in total

1.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; L Zhang; E Kostenis; C Felder; F Bymaster; J Brodkin; H Shannon; B Xia; C Deng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  The muscarinic M(5) receptor: a silent or emerging subtype?

Authors:  R M Eglen; S R Nahorski
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice.

Authors:  M Yamada; K G Lamping; A Duttaroy; W Zhang; Y Cui; F P Bymaster; D L McKinzie; C C Felder; C X Deng; F M Faraci; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

Review 4.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

5.  CaMKIIα, a modulator of M4 muscarinic acetylcholine receptors.

Authors:  Ming-Lei Guo; Zhenguo Liu; Xiang-Ping Chu; Li-Min Mao; John Q Wang
Journal:  Commun Integr Biol       Date:  2010-09

6.  An allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine.

Authors:  Ditte Dencker; Pia Weikop; Gunnar Sørensen; David P D Woldbye; Gitta Wörtwein; Jürgen Wess; Anders Fink-Jensen
Journal:  Psychopharmacology (Berl)       Date:  2012-05-31       Impact factor: 4.530

7.  M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-cyclic AMP accumulation in rat striatal slices.

Authors:  Enrique Sánchez-Lemus; José-Antonio Arias-Montaño
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

8.  Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; H Shannon; E Kostenis; C Felder; L Zhang; J Brodkin; A Grinberg; H Sheng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Modulation of agonist binding by guanine nucleotides in CHO cells expressing muscarinic m1-m5 receptors.

Authors:  P L van Giersbergen; R Leppik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

10.  In vivo competition studies of Z-(-,-)-[125I]IQNP against 3-quinuclidinyl 2-(5-bromothienyl)-2-thienylglycolate (BrQNT) demonstrating in vivo m2 muscarinic subtype selectivity for BrQNT.

Authors:  V I Cohen; B R Zeeberg; S F Boulay; V K Sood; M R Rayeq; R A Danesh; D W McPherson; R C Reba
Journal:  J Mol Neurosci       Date:  1998-08       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.